TT-223

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameTT-223
Drug Alias NameTT 223 + Epidermal growth factor analogueTT-223 + EGF analogueG1 + EGF analogueTT-223 + EGF
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionCholecystokinin B receptor antagonists
TargetsCholecystokinin B receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTransition Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOpko Health IncEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A